Previous close | 228.95 |
Open | 230.00 |
Bid | 230.07 x 800 |
Ask | 230.18 x 1200 |
Day's range | 228.84 - 230.76 |
52-week range | 156.72 - 231.86 |
Volume | |
Avg. volume | 1,257,734 |
Market cap | 65.9B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | 42.73 |
EPS (TTM) | 5.40 |
Earnings date | 30 Jul 2024 - 05 Aug 2024 |
Forward dividend & yield | 2.28 (1.00%) |
Ex-dividend date | 18 Jun 2024 |
1y target est | 238.96 |
GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.
Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.
Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.